Effect of race/ethnicity on survival in surgically treated intermediate/high risk non-metastatic clear cell renal carcinoma.

IF 2 3区医学 Q3 ONCOLOGY

Journal of Surgical Oncology Pub Date : 2024-08-25 DOI:10.1002/jso.27795

Mattia Luca Piccinelli, Cristina Cano Garcia, Andrea Panunzio, Stefano Tappero, Francesco Barletta, Reha-Baris Incesu, Zhe Tian, Stefano Luzzago, Francesco A Mistretta, Matteo Ferro, Fred Saad, Shahrokh F Shariat, Markus Graefen, Alberto Briganti, Carlo Terrone, Alessandro Antonelli, Felix K H Chun, Ottavio de Cobelli, Gennaro Musi, Pierre I Karakiewicz

{"title":"Effect of race/ethnicity on survival in surgically treated intermediate/high risk non-metastatic clear cell renal carcinoma.","authors":"Mattia Luca Piccinelli, Cristina Cano Garcia, Andrea Panunzio, Stefano Tappero, Francesco Barletta, Reha-Baris Incesu, Zhe Tian, Stefano Luzzago, Francesco A Mistretta, Matteo Ferro, Fred Saad, Shahrokh F Shariat, Markus Graefen, Alberto Briganti, Carlo Terrone, Alessandro Antonelli, Felix K H Chun, Ottavio de Cobelli, Gennaro Musi, Pierre I Karakiewicz","doi":"10.1002/jso.27795","DOIUrl":null,"url":null,"abstract":"Purpose: It is unknown to what extent 10-year overall survival of radical nephrectomy treated intermediate/high-risk non-metastatic clear cell renal carcinoma patients differs from age- and sex-matched population-based controls, especially when race/ethnicity is considered (Caucasian vs. African American vs. Hispanic vs. Asian/Pacific Islander).Methods: We relied on the SEER database (2004-2018) to identify newly diagnosed radical nephrectomy treated intermediate/high risk non-metastatic clear cell renal carcinoma patients. For each case, we simulated an age- and sex-matched control relying on Social Security Administration Life Tables with 10 years of follow-up. We compared overall survival between renal carcinoma cases and population-based controls. Multivariable competing risks regression models tested for predictors of cancer-specific mortality versus other-cause mortality.Results: Of 6877 radical nephrectomy treated intermediate/high risk non-metastatic clear cell renal carcinoma patients, 5050 (73%) were Caucasian versus 433 (6%) African American versus 1002 (15%) Hispanic versus 392 (6%) Asian/Pacific Islanders. At 10 years, overall survival difference between radical nephrectomy treated intermediate/high risk non-metastatic clear cell renal carcinoma patients versus population-based controls was greatest in African Americans (51% vs. 81%, Δ = 30%), followed by Hispanics (54% vs. 80%, Δ = 26%), Asian/Pacific Islanders (56% vs. 80%, Δ = 24%) and Caucasians (52% vs. 74%, Δ = 22%). In competing risks regression, only African Americans exhibited significantly higher other cause mortality (hazard ratio = 1.3; 95% confidence interval = 1.1 - 1.6; p = 0.01) than others.Conclusion: Relative to Life Tables' derived sex- and age-matched controls, radical nephrectomy treated intermediate/high-risk non-metastatic clear cell renal carcinoma patients exhibit worse overall survival, with worst overall survival recorded in African Americans of all race/ethnicity groups.","PeriodicalId":17111,"journal":{"name":"Journal of Surgical Oncology","volume":null,"pages":null},"PeriodicalIF":2.0000,"publicationDate":"2024-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Surgical Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/jso.27795","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: It is unknown to what extent 10-year overall survival of radical nephrectomy treated intermediate/high-risk non-metastatic clear cell renal carcinoma patients differs from age- and sex-matched population-based controls, especially when race/ethnicity is considered (Caucasian vs. African American vs. Hispanic vs. Asian/Pacific Islander).

Methods: We relied on the SEER database (2004-2018) to identify newly diagnosed radical nephrectomy treated intermediate/high risk non-metastatic clear cell renal carcinoma patients. For each case, we simulated an age- and sex-matched control relying on Social Security Administration Life Tables with 10 years of follow-up. We compared overall survival between renal carcinoma cases and population-based controls. Multivariable competing risks regression models tested for predictors of cancer-specific mortality versus other-cause mortality.

Results: Of 6877 radical nephrectomy treated intermediate/high risk non-metastatic clear cell renal carcinoma patients, 5050 (73%) were Caucasian versus 433 (6%) African American versus 1002 (15%) Hispanic versus 392 (6%) Asian/Pacific Islanders. At 10 years, overall survival difference between radical nephrectomy treated intermediate/high risk non-metastatic clear cell renal carcinoma patients versus population-based controls was greatest in African Americans (51% vs. 81%, Δ = 30%), followed by Hispanics (54% vs. 80%, Δ = 26%), Asian/Pacific Islanders (56% vs. 80%, Δ = 24%) and Caucasians (52% vs. 74%, Δ = 22%). In competing risks regression, only African Americans exhibited significantly higher other cause mortality (hazard ratio = 1.3; 95% confidence interval = 1.1 - 1.6; p = 0.01) than others.

Conclusion: Relative to Life Tables' derived sex- and age-matched controls, radical nephrectomy treated intermediate/high-risk non-metastatic clear cell renal carcinoma patients exhibit worse overall survival, with worst overall survival recorded in African Americans of all race/ethnicity groups.

查看原文本刊更多论文

种族/族裔对接受手术治疗的中度/高风险非转移性透明细胞肾癌患者生存期的影响。

目的：根治性肾切除术治疗的中/高风险非转移性透明细胞肾癌患者的10年总生存率与年龄和性别匹配的人群对照组有多大差异，尤其是在考虑种族/民族（白种人 vs. 非洲裔美国人 vs. 西班牙裔 vs. 亚洲/太平洋岛民）时，目前尚不清楚：我们依靠 SEER 数据库（2004-2018 年）确定了新诊断的根治性肾切除术治疗的中/高风险非转移性透明细胞肾癌患者。对于每个病例，我们都根据社会保障局生命表模拟了一个年龄和性别匹配、随访 10 年的对照组。我们比较了肾癌病例和人群对照组的总生存率。多变量竞争风险回归模型检验了癌症特异性死亡率与其他原因死亡率的预测因素：在 6877 名接受根治性肾切除术治疗的中/高风险非转移性透明细胞肾癌患者中，5050 人（73%）为白种人，433 人（6%）为非裔美国人，1002 人（15%）为西班牙裔美国人，392 人（6%）为亚太裔美国人。10年后，接受根治性肾切除术治疗的中/高风险非转移性透明细胞肾癌患者与人群对照组的总生存率差异最大的是非裔美国人（51%对81%，Δ = 30%），其次是西班牙裔美国人（54%对80%，Δ = 26%）、亚太裔美国人（56%对80%，Δ = 24%）和白种人（52%对74%，Δ = 22%）。在竞争风险回归中，只有非裔美国人的其他原因死亡率明显高于其他人（危险比 = 1.3；95% 置信区间 = 1.1 - 1.6；p = 0.01）：结论：与生命表得出的性别和年龄匹配对照组相比，接受根治性肾切除术治疗的中/高风险非转移性透明细胞肾癌患者的总生存率较低，所有种族/族裔群体中非洲裔美国人的总生存率最差。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Surgical Oncology 医学-外科

CiteScore

4.70

自引率

4.00%

发文量

367

审稿时长

2 months

期刊介绍： The Journal of Surgical Oncology offers peer-reviewed, original papers in the field of surgical oncology and broadly related surgical sciences, including reports on experimental and laboratory studies. As an international journal, the editors encourage participation from leading surgeons around the world. The JSO is the representative journal for the World Federation of Surgical Oncology Societies. Publishing 16 issues in 2 volumes each year, the journal accepts Research Articles, in-depth Reviews of timely interest, Letters to the Editor, and invited Editorials. Guest Editors from the JSO Editorial Board oversee multiple special Seminars issues each year. These Seminars include multifaceted Reviews on a particular topic or current issue in surgical oncology, which are invited from experts in the field.